Literature DB >> 16118074

The negative inotropic effect of esmolol on isolated cardiac muscle.

P Arlock1, B Wohlfart, T Sjöberg, S Steen.   

Abstract

OBJECTIVE: Esmolol is an ultra-short-term acting beta adrenergic blocker for intravenous use. The most common side effect is hypotension, which is often manageable by careful titration of the dose. We speculated whether esmolol had a direct negative inotropic effect on the cardiac muscle.
DESIGN: Papillary muscles and trabeculae were excised from guinea pig and pig hearts. Force production was recorded together with action potentials. Membrane currents were recorded in isolated myocytes. The effects of two concentrations of esmolol were tested (55 and 110 micromol/L).
RESULTS: Esmolol reduced action potential duration and plateau voltage, and decreased force production of isolated cardiac muscle. Voltage-clamp experiments from a holding potential of -40 mV and a step change to 0 mV showed a reduction in the inward current due to esmolol.
CONCLUSION: Apart from being a beta adrenergic blocker esmolol also exerts a direct negative inotropic effect on cardiac muscle due to its inhibition of the calcium current during the action potential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118074     DOI: 10.1080/14017430510035952

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  5 in total

1.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

2.  Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts.

Authors:  Kazutoshi Ikeshita; Kiyonobu Nishikawa; Sumiko Toriyama; Tomoyuki Yamashita; Yoshiyuki Tani; Tokuhiro Yamada; Akira Asada
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

3.  The evolutionarily conserved C-terminal peptide of troponin I is an independently configured regulatory structure to function as a myofilament Ca2+-desensitizer.

Authors:  Sienna Wong; Han-Zhong Feng; J-P Jin
Journal:  J Mol Cell Cardiol       Date:  2019-09-07       Impact factor: 5.000

4.  Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol.

Authors:  Günther Krumpl; Ivan Ulč; Michaela Trebs; Juri Hodisch; Pavla Kadlecová; Bernhard Husch
Journal:  Cureus       Date:  2020-12-22

5.  Effects of resveratrol and nebivolol on isolated vascular and cardiac tissues from young rats.

Authors:  Candice Pullen; Fiona R Coulson; Andrew Fenning
Journal:  Adv Pharmacol Sci       Date:  2014-02-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.